US › Healthcare

Precigen Inc (PGEN)

US · Healthcare · Biotechnology

$6.53-1.21%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$23.3M
Revenue YoY
+1633.9%
Net profit
$-7.9M
Profit YoY
+85.4%
EPS
$-0.02
EPS estimate
$-0.04
Net margin
-34.1%

EPS came in at -0.02 against a street estimate of -0.04 — a beat of 50.0%.

Key statistics

Market cap
$2.24B
Forward P/E
312.5
P/B
110.47
Book value
$0.06
EPS (TTM)
$-1.21
52-week high
$6.28
52-week low
$1.70
50-day MA
$4.94
200-day MA
$4.28
Beta
1.00

Analyst view

Analysts rate Precigen Inc a buy (3 buy, 0 hold, 1 sell out of 4) with an average price target of $12.45.

Shareholding

Insiders
13.71%
Institutions
71.12%

Largest institutional holders

FundStake
Patients Capital Management LLC5.00%
BlackRock Inc4.27%
State Street Corp3.05%
Vanguard Group Inc2.94%
Vanguard Capital Management, LLC2.01%
Diametric Capital, LP1.91%
Point72 Asset Management, L.P.1.86%
TANG CAPITAL MANAGEMENT LLC1.80%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Precigen Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.